Efficacy of Pudilan Xiaoyan Oral Liquid in the treatment of pneumonia induced by drug-resistant Pseudomonas aeruginosa
Abstract
Background: Pudilan Xiaoyan Oral Liquid (PDL) is a Chinese patent medicine with notable pharmacological properties, including anti-inflammatory and antibacterial effects. Drug-resistant Pseudomonas aeruginosa infection is a common and refractory bacterial infection in clinical practice. Due to its high drug resistance, it brings great challenges to treatment. This study aimed to assess the therapeutic efficacy of PDL in a murine model of pneumonia induced by drug-resistant Pseudomonas aeruginosa . Methods: Three different doses of PDL (11 mL/kg/d, 5.5 mL/kg/d, 2.75 mL/kg/d) were used to observe lung tissue pathology and inflammatory cytokine levels in pneumonia mouse models induced by multidrug-resistant Pseudomonas aeruginosa (MDR-PA). Additionally, the protective efficacy of PDL against mortality in infected mice was evaluated using a death model caused by MDR-PA. Finally sub-MIC concentration of levofloxacin was used to induce drug-resistant mice pneumonia model to evaluate the role of PDL in reversing drug resistance. Experimental data are expressed as mean ± standard deviation. Statistical significance was determined by one-way analysis of variance followed by Tukey’s multiple-comparisons test. Results: Treatment effect of PDL on MDR-PA pneumonia: the medium and small doses of PDL can significantly reduce the lung index of multi-drug resistant bacteria infected pneumonia model mice ( P < 0.05), the lung index inhibition rates for these groups were 55.09% and 58.43%, and…
Read the paper
Related studies
- Severe clinical outcomes of COVID-19 associated with proton pump inhibitors: a nationwide cohort study with propensity score matching
- Penicillins for Treatment of Pneumococcal Pneumonia: Does In Vitro Resistance Really Matter?
- Thiophenes—Naturally Occurring Plant Metabolites: Biological Activities and In Silico Evaluation of Their Potential as Cathepsin D Inhibitors
- Inhalable Mannosylated Rifampicin–Curcumin Co-Loaded Nanomicelles with Enhanced In Vitro Antimicrobial Efficacy for an Optimized Pulmonary Tuberculosis Therapy
- Development and validation of microbial bioassay for quantification of Levofloxacin in pharmaceutical preparations
- Association between cord blood 25-hydroxyvitamin D concentrations and respiratory tract infections in the first 6 months of age in a Korean population: a birth cohort study (COCOA)
Go deeper in Evidence Hub
Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.